UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Apple Turns 50: From Garage Startup to AI Crossroads 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
EAST RUTHERFORD, N.J., Aug. 30, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that company management will present at the following investor conferences in September:
2017 Wells Fargo Healthcare Conference
Date: Wednesday, September 6, 2017
Time: 4:10 p.m. EDT
Location: Boston, MA
Baird’s 2017 Global Healthcare Conference
Date: Thursday, September 7, 2017
Time: 10:15 a.m. EDT
Location: New York, NY
The live audio webcasts and slide presentations can be accessed from the Cambrex website at www.cambrex.com in the Investors section under “Webcasts & Presentations”, and replays will be available for 90 days after the live events conclude.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura Investor Relations Associate Tel: 201.804.3037 Email: [email protected]
